August 17, 2020 05:10 PM EDTUpdated February 28, 06:15 AM
R&D
FDA+

New­ly ar­rived on Nas­daq, Po­sei­da qui­et­ly sig­nals a clin­i­cal hold trig­gered by a pa­tient death in PhI — shares crater

John Carroll

Editor & Founder

Just a few weeks af­ter kick­ing off their IPO in search of build­ing a next-gen CAR-T com­pa­ny, Po­sei­da Ther­a­peu­tics $PSTX finds it­self with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

RNA gene ther­a­py start­up Shape hunts for new CEO as Se­ries C awaits

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

FDA de­lays col­orec­tal can­cer de­ci­sion for Am­gen's Lumakras, a set­back in race with Bris­tol My­ers

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times